Results 121 to 130 of about 2,507,641 (307)

Pre-Treatment SEPTIN9 Gene Methylation Ratio Predicts Tumor Response to Total Neoadjuvant Therapy in Patients with Locally Advanced Rectal Cancer

Background and objective: Multiple markers have been proposed, but there are no reliable pre-treatment markers that predict tumor response to total neoadjuvant therapy in patients with locally advanced rectal cancer.
Héctor Guadalajara, Mariano García-Arranz, Damián García-Olmo, Luz Vega-Clemente, Víctor Domínguez-Prieto, Diana Rosero-Rodríguez, Eva Ruiz-Hispán, Raquel Fuentes-Mateos, Miguel León-Arellano, Cristina Caramés, Rocío Olivera-Salazar   +10 more
core   +1 more source

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer

, 2018
This Review Article provides a multi-stakeholder view on the current status of neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in ...
Aerts, Hugo J. W. L., Jarkowski, Anthony, Travis, William D., Botwood, Nicholas, Taube, Janis M., Rusch, Valerie, Diehn, Max, Hirsch, Fred R., McCoach, Caroline E., Berry, Donald A., Stahel, Rolf A., Swisher, Stephen, Leavey, Patrick J., Blakely, Collin M., Rizvi, Naiyer A., Carbone, David P., Drezner, Nicole L., Schwartz, Lawrence H., Chaft, Jamie E., Wistuba, Ignacio I., Gianni, Luca, Perez, Edith A., Redman, Mary W., Aisner, Dara L., Bergh, Jonas, Scagliotti, Giorgio V., Eberhardt, Wilfried E. E., Blumenthal, Gideon M., Felip, Enriqueta, Cross, Darren A. E., Doebele, Robert C., Pignatti, Francesco, Prowell, Tatiana M., Keller, Steven P., Bunn, Paul A., Malik, Shakun, Keegan, Patricia, Rosell, Rafael, de Ruysscher, Dirk, Wynes, Murry W., Kris, Mark G., Sridhara, Rajeshwari, Wiens, Jacinta R.   +42 more
core   +1 more source

Autophagy Orchestrates Anti‐Tumor Immunity to Enhance Chemosensitivity via the FBXW2/C/EBPβ/TIMP‐2 Axis in Colorectal Cancer

Advanced Science, EarlyView.
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng, Chaoying Wei, Zhitong Niu, Jinxin Chen, Guojie Long, Yingzhen Weng, Qiufeng Liu, Yue Jiang, Panpan Wang, Ronghua Zhang, Qiang Yu, Xiaojian Wu, Wenyu Wang   +12 more
wiley   +1 more source

Health‐related quality of life following total minimally invasive, hybrid minimally invasive or open oesophagectomy: a population‐based cohort study

BJS (British Journal of Surgery), EarlyView., 2020
All patients operated for oesophageal cancer in Sweden from 2013 to April 2018 were identified, and 246 patients were recruited to this population‐based nationwide Swedish study. The results show that longitudinal health‐related quality of life after minimally invasive oesophagectomy was similar to that of the open surgical approach.
F. Klevebro, J. H. Kauppila, S. Markar, A. Johar, P. Lagergren   +4 more
wiley   +1 more source

CHST1 Drives Immunotherapy Resistance in Triple‐Negative Breast Cancer by Orchestrating an Immunosuppressive Microenvironment via the NKRF–CCL20–Macrophage Axis

Advanced Science, EarlyView.
Proposed model of CHST1‐associated immune remodeling in triple‐negative breast cancer. In CHST1‐low tumors, greater nuclear accumulation of NKRF is associated with repression of an NF‐κB‐related CCL20 transcriptional program and an immune‐inflamed microenvironment.
Shu‐Hao Jiang, Xiao‐Han Ying, Ruo‐Qing Wang, Qun Zhang, Li Chen, Zhi‐Ming Shao, Jun‐Jie Li   +6 more
wiley   +1 more source

Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002)

Communications Medicine
Background Hepatectomy is considered advisable for some patients with intermediate or advanced hepatocellular carcinoma (HCC). The efficacy and safety of neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors ...
Da-Long Yang, Chuang Qin, Ning Peng, Shao-Ping Liu, Ya-Qun Yu, Jun-Liang Nong, Fan-Jian Zeng, Ze Su, Yong-Yu Yang, Fu-Quan Yang, Mian-Jing Li, Ming-Song Wu, Xue-Yao Wang, Yong-Rong Liang, Fu-Xin Li, Shu-Chang Chen, Yong-Cheng Lai, Qing-Qing Pang, Teng-Meng Zhong, Yi-He Yan, Ying-Yu Zhang, Lin Ye, Xiao-Feng Dong, Wen-Feng Li, Jie Liu, Hong-Bing Yao, Pei-Sheng Wu, Xian-Shuang Mao, Jun-Jie Ou, Yao-Zhi Chen, Guo-Dong Wang, Kang Chen, Zhu-Jian Deng, Jia-Yong Su, Guo-Gao Qiu, Zhi-Dong Liu, Jin-Min Wang, Yi Zhang, Xiu-Mei Liang, Bang-De Xiang, Liang Ma, Jian-Hong Zhong, On behalf of the GUIDANCE investigators   +42 more
doaj   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better?

Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge in oncology due to its advanced stage upon diagnosis and limited treatment options.
Benjelloun El Ghali, Julie Navez, Jean-Luc Van Laethem, Rita Saúde-Conde, Christelle Bouchart   +4 more
core   +1 more source

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer

, 2016
Breast cancer is a heterogeneous disease, and the different biological subtypes have different prognostic impacts. Neoadjuvant trials have recently become popular as they offer several advantages compared to traditional adjuvant trials.
Angela Pennisi, Thomas Kieber-Emmons, Issam Makhoul, Laura Hutchins, Angela Pennisi   +4 more
core   +1 more source

Epigenetic Reactivation of TNFRSF19 Suppresses Mitophagy and Sensitizes Triple‐Negative Breast Cancer to Doxorubicin

Advanced Science, EarlyView.
TNFRSF19 is an epigenetically silenced regulator of mitophagy in triple‐negative breast cancer. TNFRSF19 deficiency activates the TGFBR1–SMAD3–PINK1 axis to promote mitophagy and confer doxorubicin resistance, whereas decitabine‐mediated restoration of TNFRSF19 suppresses mitophagy and enhances doxorubicin sensitivity, revealing a targetable epigenetic–
Shiyang Liu, Chenguang Liu, Weihong Zheng, Xiaofei Tong, Zhengwei Gui, Zonghong Lu, Sun Ieong, Lin Zhang   +7 more
wiley   +1 more source